cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Activity Oriented Therapy and Traditional Therapy in Cervical Discopathic Pain Syndrome

Title: Effectiveness of Activity Oriented Therapy and Traditional Therapy in Cervical Discopathic Pain Syndrome

Procedures: You will be asked to complete a form containing questions characterizing the study group and several questionnaires before starting treatment, such as: NDI, CESD-R, STAI and the NRS scale. A photo of the head and shoulder area will also be taken in a front and side standing position. After completing the two-week treatment, you will be asked again to complete questionnaires and pose for photos. You will be informed about a follow-up visit 3 months after the end of therapy, during which you will be asked for the last time to complete questionnaires and pose for a photo.

Benefits: There are no direct benefits to you other than participating in a therapy more commonly used for cervical pain syndromes and the opportunity to discuss your experience with neck pain with a specialist. The information we obtain will help scientists better understand the problem of treating neck pain.

Risk: There are no physical risks to you while conducting this research. All information obtained from you will be anonymous. Your name and image will not be used in this study or reports.

Confidentiality: All research records will be confidential and appropriately secured. Records will only be published with your consent or by court order or as required by law. Any publication resulting from this research will not use identifying information, such as your name or likeness.

Freedom to opt out: Participation in the study is completely voluntary and free of charge. You may withdraw from this study at any time without any consequences.

The purpose of the study was to evaluate the effectiveness of the Activity Oriented Therapy (N.A.P. therapy) and traditional therapy during disc-related neck pain in terms of pain intensity, disability, Forward Head Posture (FHP), anxiety as a condition and level of depression. Patients were qualified based on a medical examination. Respondents were randomly divided into two groups.

The therapies were performed by experienced physiotherapists in cooperation with a psychologist. Treatment in both groups included 10 therapy sessions held daily from Monday to Friday over a two-week period.

Eligibility Criteria:
Inclusion Criteria:

* qualifying: non-traumatic, disc-like, chronic (symptoms lasting more than 3 months) cervical pain of mechanical origin, localized in the cervical region with the possibility of radiation to the upper edge of the scapula and head (without root symptoms and neurological disorders), classified as syndrome No. 1 according to the Quebec Task Force (QTF) Classification, and a condition not requiring surgery.

Exclusion Criteria:

* comorbid advanced neurological, rheumatic, urological, psychiatric diseases, and unsystematic participation in in therapy.
Perineal Preparation for Pregnant Ladies.

Pregnant participants will be recruited at the obstetrics outpatient clinic during their visits 4 weeks before the due date. They are randomized into two groups. The first group will be educated to do digital perineal massage. They will be also educated to do pelvic floor muscle exercises and will receive the usual education program for strengthening the pelvic floor. The second group will receive the usual education program for strengthening the pelvic floor. Occurrence of perineal laceration will be reported at time of delivery.

Pregnant participants will be recruited at the obstetrics outpatient clinic during their visits 4 weeks before the due date. They are randomized into two groups. The first group will be educated to do digital perineal massage. They will be also educated to do pelvic floor muscle exercises and will receive the usual educational pelvic floor dysfunction prevention program for strengthening the pelvic floor. The second group will receive the usual education program for strengthening the pelvic floor. Occurrence of perineal laceration will be reported at time of delivery.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women ≥ 35 years old
* Primigravida or multi gravida

Exclusion Criteria:

* History of chronic constipation
* History of chronic cough
* Current or past urinary or anal incontinence
* History of genital prolapse before pregnancy
* History of neuromuscular disorders or connective tissue disorders
* History of medical disorders
* History of preterm or precipitate labour
* History of premature preterm rupture of membranes.
* Genital infections
Analysis of Prognostic Cell Signaling Factors in Adolescent Idiopathic Scoliosis

The purpose of this study is to identify potential markers for curve progression in adolescent idiopathic scoliosis (AIS). Despite its prevalence and impact on child health, the etiology of AIS and molecular mechanisms underlying its development and progression remain poorly understood. Clinical criteria and features cannot adequately predict which children, diagnosed with mild disease, will undergo subsequent curve progression requiring intervention.

The investigators hypothesize that alterations in specific genetic markers will be correlated with the progression of AIS curves over time. Thus, these markers could be used in the future to develop a reliable, inexpensive and relatively non-invasive cell based diagnostic test to (1) predict spinal curve progression in AIS, (2) select patients likely to benefit from early surgical intervention, and (3) potentially screen for asymptomatic children at risk of developing idiopathic scoliosis.


Eligibility Criteria:
Inclusion Criteria:

* Females aged 10-13 years
* Diagnosed with mild-moderate spine deformity (Cobb angle 15-30 degrees)

Exclusion Criteria:

* Patients with scoliosis other than idiopathic
* Trauma
* Inflammatory disease
* Malignancies
* Diabetes
* History of previous spine surgery
Arthroscopic Repair Versus High Tibial Osteotomy for Medial Meniscus Posterior Root Tears

The goal of the trial is to compare Arthroscopic repair against Opening wedge high tibial osteotomy for Medial Meniscus posterior root tears

All Patients included in this clinical trial will be informed by written consent will undergo a one week screening to determine the eligibility for study entry.

Patients who meet the eligibility requirements will be randomized in a single blinded manner (patients).

Eligibility Criteria:
Inclusion Criteria:

* Sex: both sexes.
* Age: Above 40
* Degree of Varus: Neutral to 10 degrees of Varus

Exclusion Criteria:

* History of high energy trauma.
* Multiligamentous knee Injury.
Doripenem in the Treatment of Complicated Intra-Abdominal Infections

The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.

Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3, multicenter, prospective, randomized, double-blind study of intravenous doripenem versus a comparator antibiotic to assess the effectiveness and safety of doripenem in the treatment of complicated intra-abdominal infections in hospitalized adults. The primary endpoint is the clinical response rate measured at late follow-up visit. The patients will receive either doripenem or comparator; treatment duration is 5 to 14 days.

Eligibility Criteria:
Inclusion Criteria:

* Has a requirement for surgical intervention within 24 hours of study entry
* Requirement of antibacterial therapy in addition to surgical intervention in certain intra-abdominal infections.

Exclusion Criteria:

* Female patients who are pregnant, nursing, or if of child bearing potential not using a medically accepted, effective method of birth control
* Any rapidly-progressing disease or immediately life-threatening illness.
Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave Doppler Ultrasound

The objective of the trial was to evaluate velocity-associated parameters of pulsed-wave Doppler ultrasound at induction, discharge from the post-anaesthesia care unit and during inspiratory cough in addition to the consumption of phenylephrine during the operation in patients undergoing video-assisted thoracic surgery with three types of anaesthesia management.

The objective of the trial was to evaluate velocity-associated parameters of pulsed-wave Doppler ultrasound at induction, discharge from the post-anaesthesia care unit and during inspiratory cough in addition to the consumption of phenylephrine during the operation in patients undergoing video-assisted thoracic surgery with three types of anaesthesia management. The patients in this trial were visited during the entire operation and just before leaving the post-anaesthesia care unit. Velocity-associated data related to pulsed-wave Doppler ultrasound and the consumption of phenylephrine were collected.

Eligibility Criteria:
Inclusion Criteria:

1. ethnic Chinese;
2. age, 18 to 65 years old;
3. American Society of Anaesthesiologists (ASA) physical status I or II;
4. required VATS for lung surgery and one lung ventilation .

Exclusion Criteria:

body mass index exceeding 30 kg/m2; Patients with a history of hypertension, diabetes mellitus or arteriosclerosis; and any allergy to drugs used in the study.

Patients with arrhythmias or implanted cardiac pacemakers were excluded. Patients with diseases of the central or peripheral nervous system were excluded.

Patients taking medications affecting the autonomic nervous system, such as b-blockers and calcium channel blockers
Developing Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia

Negative symptoms are core symptoms in schizophrenia which play an important role in clinical outcomes and impede patients to return to society. Anti-psychotic medicines have shown limited effect in improving negative symptoms and cognitive functioning, whereas non-invasive neuromodulations, i.e. , transcranial alternating current stimulation (tACS), have shown promising potentials. Recently new evidence of brain structural and functional alterations has been provided by neuroimaging studies. Brady RO et al. found cerebellar-prefrontal network connectivity was related to negative symptoms in schizophrenia. It provides clues for developing a new tACS protocol targeting improving negative symptoms, in which dual-channel high-density alternating current stimulations were delivered over both the right dorsolateral prefrontal cortex and cerebellum simultaneously.


Eligibility Criteria:
Inclusion Criteria:

* meet the DSM-V diagnostic criteria for schizophrenia;
* present with prominent negative symptoms with PANSS-negative scores \>20, at least one score of PANSS N1-N7 \>3, and reductive ratio of PANSS-negative in the past two weeks before recruitment \<10%;
* stable usage and dosage of anti-psychotic medicines in the past two weeks and during the tACS intervention.
* age within 18-60;
* illness duration \>1year;
* education at least 6 years;
* written consent of receiving tACS intervention.

Exclusion Criteria:

* Meet any DSM-V diagnostic criteria of any other psychiatric disorders besides schizophrenia ;
* any history of alcohol or substance dependence in the past 3 months;
* any other major physical disease (i.e., Sensorimotor disorder, neurological disease);
* any metal implants or any other tACS contraindication.
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia or schizoaffective disorder

Exclusion Criteria:

* ECT in the last 6 months
* Substance abuse or dependence
* History of claustrophobia
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia

Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6 mg/kg/d, days 1-4; arm B). The primary endpoint is duration of remission defined as platelets ≥50/nl.

Patients above the age of 18 years with a first episode of immune thrombocytopenia (ITP) are eligible for inclusion, except pregnant women and patients unable to tolerate glucocorticoids. Diagnosis is made and treatment requirement defined according to the 1996 practice guidelines of the American Society of Hematology. The primary endpoint is duration of remission defined as platelets ≥50/nl. Secondary endpoints are response rate, complete remission (platelets ≥150/nl), cumulative cortisol equivalent dose (potency of prednisone / dexamethasone relative to cortisol: x 4 / x 30) and adverse events. During the first week of treatment all patients receive prednisone at 1 mg/kg/d. This period is used to confirm the diagnosis and identify patients with ITP secondary to lymphoproliferative, autoimmune (systemic lupus erythematosus, antiphospholipid syndrome) or infectious diseases (human immunodeficiency, hepatitis C, cytomegalovirus infection). Patients are stratified by age (cut-off: 50 years), gender and primary versus secondary ITP and then randomized 1:1 between daily prednisone (arm A) and pulsed dexamethasone (arm B). In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to \<25 mg/d by week 14 and \<7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above. In arm B patients receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4). Patients failing to achieve or maintain a remission are switched to the alternative treatment arm (A: no response after 4 weeks of prednisone at 1-2 mg/kg/d, loss of response, maintenance doses exceeding the above limits; B: no response after 2 cycles, loss of response).

Eligibility Criteria:
Inclusion Criteria:

* First episode of ITP

Exclusion Criteria:

* Pregnancy
* Glucocorticoid intolerance
The Effect of HealthWear on Short-Term Weight Loss

The purpose of this study is to examine the effect of a computer tracking system and energy expenditure device on weight loss in adults.


Eligibility Criteria:
Inclusion Criteria:

1. 18-55 years of age.
2. Body mass index (BMI) between 25.0-39.9 kg/m2.
3. Access to a computer, Internet access, and will demonstrate proficiency with using the Internet and Web-based software programs. Potential participants will be asked to provide the type of computer they have, the name of their internet service provider, and will have to demonstrate their ability to search the internet during their screening visit.

Exclusion Criteria:

1. Report losing \>5% of current body weight in the previous 6 months.
2. Report participating in a research project involving weight loss or physical activity in the previous 6 months.
3. For women, report being pregnant during the previous 6 months, or planning on becoming pregnant over the following 3 months of the intervention. (Pregnancy during initial screening will be based on self-report and will be included on the detailed medical history that is completed by subjects. In addition, this will also be obtained as part of the signed medical clearance from the individual's personal physician.)
4. Currently being treated for any medical condition that could impact body weight (i.e., diabetes mellitus, cancer, etc.).
5. History of myocardial infarction, or a history of undergoing heart surgery such as bypass or angioplasty.
6. Taking medication that would affect heart rate or blood pressure responses to exercise (e.g., beta blockers).
7. Taking medication that could affect metabolism and/or contribute to a change in body weight (e.g., synthroid).
8. Being treated by a therapist for psychological issues or problems, taking pyschotropic medications, or receiving treatment with psychotropic medications within the previous 6 months.
9. No exclusion criteria shall be based on race, ethnicity, or gender.
Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients

To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV negative heart recipients who are currently listed.


Eligibility Criteria:
Inclusion Criteria:

* Male or female
* Age 18 and older
* Active on the transplant list
* Donor organ with Antibody and NAT (nucleic acid test) positive for HCV
* HCV negative recipient; this includes patients who never had HCV and those with HCV previously eradicated with antiviral therapy. The latter is defined as those with undetectable HCV viral load at least 3 months since stopping therapy.
* Willing and able to provide written informed consent or for those subjects where hepatic encephalopathy affects their ability to provide initial or ongoing consent, has an appropriate and legally-authorized representative willing and able to provide consent on behalf of the subject
* Patients listed for multiple organ transplant (heart and kidney or heart and liver) can be included based on agreement of non-cardiac organ transplant team

Exclusion Criteria:

* Participants co-infected with HIV
* Donor previously treated with an NS5a containing regimen (if treatment history of donor known)
* Known allergies or hypersensitivity to DAA or ribavarin
* Pregnancy and/or actively breastfeeding
Proton Therapy for Lymph Nodes in Breast Cancer

The purpose of this study is to determine if proton radiation therapy will reduce the amount of heart that is exposed to radiation, thereby decreasing the frequency and/or severity of any cardiac side effects.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed invasive adenocarcinoma of the breast stage I-III (TX, T0-4, N0-3) with medially located tumor and/or axillary node invasion.
* Patients must have undergone either mastectomy or breast conservation surgery.
* Patients are required to have axillary staging which can include sentinel node biopsy alone if sentinel node is negative.
* Patient must require peripheral lymph node radiation per physician discretion.

Exclusion Criteria:

* Evidence of distant metastasis (M1).
* Prior radiotherapy to the area of interest.
* Prior history of cardiovascular disease per physician discretion.
* Prior or concurrent cancer other than non-melanomatous skin cancer unless disease free for at least 5 years.
* Collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis or scleroderma.
AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation

Testing of AI solutions to assess diagnostic accuracy for tuberculosis detection.

Tuberculosis remains a key problem of modern medicine. New approaches for burden overcoming should be proposed. New screening strategies may include artificial intelligence (AI). An AI-based system for chest x-ray analysis and triage ("normal/tuberculosis suspected") have been developed and trained. A special data-set was prepared. There are 238 normal x-rays and 70 x-rays with lung tuberculosis in data-set. The data-set was randomly divided into 2 samples:

* sample N1 (n=140) with ratio "normal: tuberculosis" 50:50,
* sample N1 (n=150) with ratio "normal: tuberculosis" 95:5. Both samples will be analysed by AI-based system. Results will be quantified using diagnostic accuracy metrics: sensitivity and specificity, positive and negative predictor values, likelihood ratio, and area under the ROC (receiver operating characteristic) curve.

Eligibility Criteria:
Inclusion Criteria:

* no pathology in a lung on chest x-ray
* signs of lung tuberculosis on chest x-ray

Exclusion Criteria:

* any pathology in the lungs (except tuberculosis)
STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS

This study will be based on two questionnaires

1. One specific questionnaire that has already been developed from social sciences interviews conducted in men who have been treated for localized prostrate cancer, with a good or intermediate prognosis. This questionnaire comprises 11 pairs of scenarios. Each scenario gathers in a random manner, the modalities of 7 possible characteristics of the management strategy for localized prostrate cancer, with a good or intermediate prognosis:

   * the risk of death at 5 years (modalities: 5%, 15%),
   * the risk of impotence (modalities: 0%, 25%, 50%, 75%),
   * the presence of urinary leaks (modalities: no protection during the day, one protection pad per day, several protection pads per day),
   * the duration and frequency of care provided (modalities: 2 days of care in your whole life, 7 days of care in your whole life, 5 half-days of care per week for 8 weeks, every 3 months for 2 years then every 6 months for life),
   * ablation of the prostate (modalities: Yes, No),
   * the existence of possible treatments in case of aggravation or recurrence (modalities: Yes, No),
   * the nature of the technology used (modalities: innovative technology, standard technology).

   The objective is to ask each participant of the study for each pair of scenarios, to choose from the two scenarios (binary-choice survey), the scenario he prefers.
2. The "Spielberger Inventory Trait" scale to evaluate stable characteristics in the propensity to anxiety in study participants.


Eligibility Criteria:
Inclusion Criteria:

Men:

* aged 50 to 70 years
* seen at a urology consultation
* able to understand written and spoken French
* who have provided written informed consent

Exclusion Criteria:

Men:

* under guardianship or wards of court
* who have already been diagnosed withor treated for prostrate cancer
* with recently diagnosed cancer or on treatment for this cancer